Medicine

FDA names Kathleen Uhl acting director, office of generic drugs

• Bookmarks: 4


(Reuters) – The Food and Drug Administration has named Dr. Kathleen Uhl acting director of its Office of Generic Drugs as it initiates a nationwide search for a full-time replacement for Dr. Gregory Geba, who resigned last week.

The announcement was made on Tuesday in a note to staff from Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. Dr. Uhl most recently served as Geba’s senior adviser.

(Reporting by Toni Clarke in Washington- Editing by Gerald E. McCormick)

4 recommended
comments icon0 comments
0 notes
48 views
bookmark icon

Write a comment...

Your email address will not be published. Required fields are marked *